The Zhitong Finance App learned that Iambic Therapeutics (IAM.US), a biotechnology company that develops small-molecule anti-cancer therapies based on self-developed artificial intelligence (AI) platforms and is in the first phase of clinical trials, announced its IPO terms on Thursday. The San Diego, California-based company plans to raise $150 million by issuing 9.4 million shares, with an issue price range of $15 to $17 per share. Some investors have indicated that they intend to subscribe for shares worth 60 million US dollars (40% of the deal) in this offering. Based on the median value of the proposed issuance price range, Iambic Therapeutics' fully diluted market value will reach US$809 million.

Zhitongcaijing · 1d ago
The Zhitong Finance App learned that Iambic Therapeutics (IAM.US), a biotechnology company that develops small-molecule anti-cancer therapies based on self-developed artificial intelligence (AI) platforms and is in the first phase of clinical trials, announced its IPO terms on Thursday. The San Diego, California-based company plans to raise $150 million by issuing 9.4 million shares, with an issue price range of $15 to $17 per share. Some investors have indicated that they intend to subscribe for shares worth 60 million US dollars (40% of the deal) in this offering. Based on the median value of the proposed issuance price range, Iambic Therapeutics' fully diluted market value will reach US$809 million.